Sino Biopharmaceutical Ltd
HKEX:1177
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.34
4.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Sino Biopharmaceutical Ltd
Sino Biopharmaceutical Ltd
Income from Continuing Operations
Sino Biopharmaceutical Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Income from Continuing Operations
¥4.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
12%
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Income from Continuing Operations
HK$2.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Income from Continuing Operations
¥2.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
27%
|
CAGR 10-Years
18%
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Income from Continuing Operations
¥993.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
12%
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Income from Continuing Operations
HK$13.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Income from Continuing Operations
-$42.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
See Also
What is Sino Biopharmaceutical Ltd's Income from Continuing Operations?
Income from Continuing Operations
4.9B
CNY
Based on the financial report for Jun 30, 2024, Sino Biopharmaceutical Ltd's Income from Continuing Operations amounts to 4.9B CNY.
What is Sino Biopharmaceutical Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
12%
Over the last year, the Income from Continuing Operations growth was 26%. The average annual Income from Continuing Operations growth rates for Sino Biopharmaceutical Ltd have been -26% over the past three years , -15% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet
